Parabilis Medicines, Inc. (PBLS)

39.58 +0.58 (+1.47%) USD  |  NASDAQ  |  Sep 01, 16:00
39.58 0.00 (0.00%) After-Hours: 18:59
More

Parabilis Medicines Total Long Term Debt (Quarterly) : 34.21M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for PBLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2025. Start Trial.
Date Value
June 30, 2026 34.21M
March 31, 2026 36.37M
Date Value
June 30, 2025 0.00
March 31, 2025 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Moderna, Inc. 1.266B
Kailera Therapeutics, Inc. 9.166M
Arrowhead Pharmaceuticals, Inc. 1.371B
Oncolytics Biotech, Inc. 0.31M
Sangamo Therapeutics, Inc. 19.33M